tiprankstipranks
Roivant Sciences Ltd. (ROIV)
NASDAQ:ROIV
US Market
ROIV
Roivant Sciences
RESEARCH TOOLSreports
Want to see ROIV full AI Analyst Report?

Roivant Sciences (ROIV) Stock Forecast & Price Target

730 Followers
See the Price Targets and Ratings of:

ROIV Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Roivant
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ROIV Stock 12 Month Forecast

Average Price Target

$37.83
▲(26.83% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $37.83 with a high forecast of $42.00 and a low forecast of $31.50. The average price target represents a 26.83% change from the last price of $29.83.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","26":"$26","43":"$43","17.5":"$17.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.83333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,17.5,26,34.5,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.09,30.083076923076923,31.076153846153847,32.06923076923077,33.06230769230769,34.05538461538462,35.04846153846154,36.041538461538465,37.034615384615385,38.027692307692305,39.02076923076923,40.01384615384615,41.00692307692307,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.09,29.762564102564102,30.435128205128205,31.107692307692307,31.78025641025641,32.45282051282051,33.12538461538461,33.797948717948714,34.470512820512816,35.14307692307692,35.81564102564102,36.488205128205124,37.160769230769226,{"y":37.83333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.09,29.275384615384617,29.46076923076923,29.646153846153847,29.83153846153846,30.016923076923078,30.20230769230769,30.38769230769231,30.573076923076922,30.75846153846154,30.943846153846152,31.12923076923077,31.314615384615387,{"y":31.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.83,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$42.00Average Price Target$37.83Lowest Price Target$31.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on ROIV
Yatin Suneja
Guggenheim
Guggenheim
$30→$36
Buy
20.68%
Upside
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Crescent Biopharma (NASDAQ: CBIO) and Genmab (NASDAQ: GMAB)
J.P. Morgan Analyst forecast on ROIV
Brian Cheng
J.P. Morgan
J.P. Morgan
$35→$40
Buy
34.09%
Upside
Reiterated
05/26/26
Roivant Sciences price target raised to $40 from $35 at JPMorganRoivant Sciences price target raised to $40 from $35 at JPMorgan
Bank of America Securities Analyst forecast on ROIV
Chi Meng Fong
Bank of America Securities
Bank of America Securities
$29.5→$31.5
Hold
5.60%
Upside
Reiterated
05/25/26
Roivant Sciences price target raised to $31.50 from $29.50 at BofARoivant Sciences price target raised to $31.50 from $29.50 at BofA
TD Cowen Analyst forecast on ROIV
Yaron Werber
TD Cowen
TD Cowen
$38→$41
Buy
37.45%
Upside
Assigned
05/21/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV) and Citius Oncology (NASDAQ: CTOR)
Piper Sandler Analyst forecast on ROIV
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$40
Buy
34.09%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Roivant Sciences (NASDAQ: ROIV)
H.C. Wainwright Analyst forecast on ROIV
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$34
Buy
13.98%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Kindly MD (NASDAQ: NAKA) and Roivant Sciences (NASDAQ: ROIV)
Citi Analyst forecast on ROIV
Samantha Semenkow
Citi
Citi
$35→$42
Buy
40.80%
Upside
Reiterated
05/21/26
Roivant Sciences price target raised to $42 from $35 at CitiRoivant Sciences price target raised to $42 from $35 at Citi
Goldman Sachs Analyst forecast on ROIV
Corinne Johnson
Goldman Sachs
Goldman Sachs
$38→$41
Buy
37.45%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Ovid Therapeutics (NASDAQ: OVID) and Legend Biotech (NASDAQ: LEGN)
Bernstein Analyst forecast on ROIV
William Pickering
Bernstein
Bernstein
$35
Buy
17.33%
Upside
Initiated
03/20/26
Roivant Sciences initiated with an Outperform at BernsteinRoivant Sciences initiated with an Outperform at Bernstein
Jefferies Analyst forecast on ROIV
Dennis Ding
Jefferies
Jefferies
$24→$30
Buy
0.57%
Upside
Reiterated
02/09/26
Roivant Sciences price target raised to $30 from $24 at JefferiesRoivant Sciences price target raised to $30 from $24 at Jefferies
Leerink Partners Analyst forecast on ROIV
David Risinger
Leerink Partners
Leerink Partners
$22→$32
Buy
7.27%
Upside
Reiterated
12/15/25
Roivant Sciences: Promising Future with Strong Pipeline and Financial Stability
Cantor Fitzgerald Analyst forecast on ROIV
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
06/18/25
Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on ROIV
Yatin Suneja
Guggenheim
Guggenheim
$30→$36
Buy
20.68%
Upside
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Crescent Biopharma (NASDAQ: CBIO) and Genmab (NASDAQ: GMAB)
J.P. Morgan Analyst forecast on ROIV
Brian Cheng
J.P. Morgan
J.P. Morgan
$35→$40
Buy
34.09%
Upside
Reiterated
05/26/26
Roivant Sciences price target raised to $40 from $35 at JPMorganRoivant Sciences price target raised to $40 from $35 at JPMorgan
Bank of America Securities Analyst forecast on ROIV
Chi Meng Fong
Bank of America Securities
Bank of America Securities
$29.5→$31.5
Hold
5.60%
Upside
Reiterated
05/25/26
Roivant Sciences price target raised to $31.50 from $29.50 at BofARoivant Sciences price target raised to $31.50 from $29.50 at BofA
TD Cowen Analyst forecast on ROIV
Yaron Werber
TD Cowen
TD Cowen
$38→$41
Buy
37.45%
Upside
Assigned
05/21/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV) and Citius Oncology (NASDAQ: CTOR)
Piper Sandler Analyst forecast on ROIV
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$40
Buy
34.09%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Roivant Sciences (NASDAQ: ROIV)
H.C. Wainwright Analyst forecast on ROIV
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$34
Buy
13.98%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Kindly MD (NASDAQ: NAKA) and Roivant Sciences (NASDAQ: ROIV)
Citi Analyst forecast on ROIV
Samantha Semenkow
Citi
Citi
$35→$42
Buy
40.80%
Upside
Reiterated
05/21/26
Roivant Sciences price target raised to $42 from $35 at CitiRoivant Sciences price target raised to $42 from $35 at Citi
Goldman Sachs Analyst forecast on ROIV
Corinne Johnson
Goldman Sachs
Goldman Sachs
$38→$41
Buy
37.45%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Ovid Therapeutics (NASDAQ: OVID) and Legend Biotech (NASDAQ: LEGN)
Bernstein Analyst forecast on ROIV
William Pickering
Bernstein
Bernstein
$35
Buy
17.33%
Upside
Initiated
03/20/26
Roivant Sciences initiated with an Outperform at BernsteinRoivant Sciences initiated with an Outperform at Bernstein
Jefferies Analyst forecast on ROIV
Dennis Ding
Jefferies
Jefferies
$24→$30
Buy
0.57%
Upside
Reiterated
02/09/26
Roivant Sciences price target raised to $30 from $24 at JefferiesRoivant Sciences price target raised to $30 from $24 at Jefferies
Leerink Partners Analyst forecast on ROIV
David Risinger
Leerink Partners
Leerink Partners
$22→$32
Buy
7.27%
Upside
Reiterated
12/15/25
Roivant Sciences: Promising Future with Strong Pipeline and Financial Stability
Cantor Fitzgerald Analyst forecast on ROIV
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
06/18/25
Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roivant Sciences

3 Months
Brian ChengJ.P. Morgan
Success Rate
14/20 ratings generated profit
70%
Average Return
+18.18%
Copying Brian Cheng's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +18.18% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
32/35 ratings generated profit
91%
Average Return
+69.26%
Copying David Risinger's trades and holding each position for 1 Year would result in 91.43% of your transactions generating a profit, with an average return of +69.26% per trade.
2 Years
David RisingerLeerink Partners
Success Rate
34/35 ratings generated profit
97%
Average Return
+115.46%
Copying David Risinger's trades and holding each position for 2 Years would result in 97.14% of your transactions generating a profit, with an average return of +115.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ROIV Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
0
0
0
0
Buy
11
13
17
16
10
Hold
1
2
2
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
15
19
19
12
In the current month, ROIV has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ROIV average Analyst price target in the past 3 months is 37.83.
Each month's total comprises the sum of three months' worth of ratings.

ROIV Financial Forecast

ROIV Earnings Forecast

Next quarter’s earnings estimate for ROIV is -$0.30 with a range of -$0.47 to -$0.12. The previous quarter’s EPS was $0.28. ROIV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ROIV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ROIV is -$0.30 with a range of -$0.47 to -$0.12. The previous quarter’s EPS was $0.28. ROIV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ROIV has Performed in-line its overall industry.

ROIV Sales Forecast

Next quarter’s sales forecast for ROIV is $2.32M with a range of $0.00 to $5.00M. The previous quarter’s sales results were $2.52M. ROIV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ROIV has Performed in-line its overall industry.
Next quarter’s sales forecast for ROIV is $2.32M with a range of $0.00 to $5.00M. The previous quarter’s sales results were $2.52M. ROIV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ROIV has Performed in-line its overall industry.

ROIV Stock Forecast FAQ

What is ROIV’s average 12-month price target, according to analysts?
Based on analyst ratings, Roivant Sciences Ltd.’s 12-month average price target is 37.83.
    What is ROIV’s upside potential, based on the analysts’ average price target?
    Roivant Sciences Ltd. has 26.83% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ROIV a Buy, Sell or Hold?
          Roivant Sciences Ltd. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Roivant Sciences Ltd.’s price target?
            The average price target for Roivant Sciences Ltd. is 37.83. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $42.00 ,the lowest forecast is $31.50. The average price target represents 26.83% Increase from the current price of $29.83.
              What do analysts say about Roivant Sciences Ltd.?
              Roivant Sciences Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of ROIV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.